Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways

por Itzhak, Inbal, Bareket-Samish, Avital, Fishman, Pnina
Publicado 2023

Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A(3) Adenosine Receptor Agonist Piclidenoson

por Cohen, Shira, Barer, Faina, Itzhak, Inbal, Silverman, Michael H., Fishman, Pnina
Publicado 2018

The A3 adenosine receptor agonist, namodenoson, ameliorates non-alcoholic steatohepatitis in mice

por Fishman, Pnina, Cohen, Shira, Itzhak, Inbal, Amer, Johnny, Salhab, Ahmad, Barer, Faina, Safadi, Rifaat
Publicado 2019

Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis

por Safadi, Rifaat, Braun, Marius, Francis, Adi, Milgrom, Yael, Massarwa, Muhammad, Hakimian, David, Hazou, Wadi, Issachar, Assaf, Harpaz, Zivit, Farbstein, Motti, Itzhak, Inbal, Lev‐Cohain, Naama, Bareket‐Samish, Avital, Silverman, Michael H., Fishman, Pnina
Publicado 2021

Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

por Stemmer, Salomon M., Manojlovic, Nebojsa S., Marinca, Mihai Vasile, Petrov, Petar, Cherciu, Nelly, Ganea, Doina, Ciuleanu, Tudor Eliade, Pusca, Ioana Adriana, Beg, Muhammad Shaalan, Purcell, William T., Croitoru, Adina-Emilia, Ilieva, Rumyana Nedyalkova, Natošević, Sladjana, Nita, Amedeia Lavinir, Kalev, Dimitar Nikolaev, Harpaz, Zivit, Farbstein, Motti, Silverman, Michael H., Bristol, David, Itzhak, Inbal, Fishman, Pnina
Publicado 2021